New Publication in Vaccine

Vaccines and AMR: An analysis of the funding landscape for human bacterial vaccines in low-and middle-income countries

 

We are proud to have collaborated with the International Vaccines Institute and G-Finder to deliver this first comprehensive analysis of the research funding landscape for the development of  human bacterial vaccines in low and middle income countries.

Publicly available funding data from the G-FINDER and Global AMR R&D Hub databases, were examined, covering projects active between January 2007 and January 2024. The study identifies funding recipients, geographic distribution, and the role of intermediary organizations in bacterial vaccine R&D.

Key Findings

  • $4.5 billion invested globally in bacterial vaccine R&D, primarily targeting M. tuberculosis and S. pneumoniae.
  • Most funding was allocated to organizations in North America and Europe, while Asia, Africa, and Central/South America collectively received less than 20%.
  • Philanthropic and intermediary organizations, particularly Product Development Partnerships (PDPs), play a critical role in channeling funds to LMICs and advancing vaccine development.

Looking Ahead

Transparent reporting is essential to accurately track funding flows to LMICs. While PDPs and intermediary funders are instrumental in bridging investment gaps, significant funding shortfalls remain for key bacterial pathogens on WHO’s bacterial priority pathogen list. Strengthening global collaboration and targeted investments will be crucial in addressing these gaps and ensuring equitable vaccine development.

 


Curious about more?

You can sign up for our newsletter here. By subscribing, you automatically provide your consent for the use of your data in accordance with our privacy policy.

This field is for validation purposes and should be left unchanged.

Latest news

Go to all news
Dynamic Dashboard